

10/505,476

=> file caplus
FILE 'CAPLUS' ENTERED AT 15:28:17 ON 22 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Feb 2006 VOL 144 ISS 9
FILE LAST UPDATED: 21 Feb 2006 (20060221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 7 SEA FILE=REGISTRY SSS FUL L1
L4 3 SEA FILE=CAPLUS L3

=> d l4 1-3 ibib abs hitstr


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:757699 CAPLUS
DOCUMENT NUMBER: 139:276898
TITLE: Preparation of imidazolinylpyridone derivatives as NPY receptor antagonists
INVENTOR(S): Sato, Nagaaki; Nagase, Tsuyoshi; Nagai, Keita; Ando, Makoto; Kanatani, Akio
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2003078422	A1	20030925	WO 2003-JP3115	20030314
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479141	AA	20030925	CA 2003-2479141	20030314
AU 2003221394	A1	20030929	AU 2003-221394	20030314
EP 1486497	A1	20041215	EP 2003-710371	20030314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005154025	A1	20050714	US 2003-505476	20030314
PRIORITY APPLN. INFO.:			JP 2002-73120	A 20020315
			WO 2003-JP3115	W 20030314

OTHER SOURCE(S) : MARPAT 139:276898

GI



AB The title compds. with general formula of I [wherein R1 = H, halo, CN, alkyl, haloalkyl, OH, alkoxy, or aralkyloxy; R2 and R3 = independently H, halo, or haloalkyl; R4 and R5 = independently H or halo; with exclusions] and salts thereof are prepared as neuropeptide Y (NPY) receptor antagonists. I are useful as a therapeutic agent for various diseases in which NPY participates, e.g., overeating, obesity, or diabetes (no data). Thus, the compound II was prepared in a multi-step synthesis. II showed IC50 of 2.8 nM against human NPY. Formulations containing I as an active ingredient were also described.


IT 604773-87-7P 604773-89-9P 604773-91-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of imidazolinylpyridone derivs. as NPY receptor antagonists)

RN 604773-87-7 CAPLUS

CN 2(1H)-Pyridinone, 6-[(4R,5S)-4-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 604773-89-9 CAPLUS

CN 2(1H)-Pyridinone, 5-fluoro-6-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 604773-91-3 CAPLUS

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4,5-dihydro-5-methyl-4-[6-(trifluoromethyl)-3-pyridinyl]-1H-imidazol-2-yl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 604773-95-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of imidazolinylpyridone derivs. as NPY receptor antagonists)

RN 604773-95-7 CAPLUS

CN Pyridine, 6-[(5S)-4-(4-fluorophenyl)-4,5-dihydro-5-methyl-4-[6-(trifluoromethyl)-3-pyridinyl]-1H-imidazol-2-yl]-3-methyl-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:132359 CAPLUS
 DOCUMENT NUMBER: 138:187642
 TITLE: Preparation of pyridyl-1,2-ethanediamines as intermediates for NPY receptor antagonists
 INVENTOR(S): Takahashi, Hirofumi; Sato, Nagaaki; Nagai, Keita; Jitsuoka, Makoto; Uchiito, Shihō; Fukami, Takehiro
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003048875	A2	20030221	JP 2001-233519	20010801
PRIORITY APPLN. INFO.:			JP 2001-233519	20010801

OTHER SOURCE(S): MARPAT 138:187642
 AB The compds. NH₂CR₁pAr₁pCR₂pR₃pNH₂ [Ar₁p = (un)substituted aryl, heteroaryl; R₁p = lower cycloalkyl, (un)substituted aryl, heteroaryl; R₂p, R₃p = H, lower cycloalkyl, lower alkenyl, (un)substituted lower alkyl; if R₂p = R₃p = H, then both of Ar₁p and R₁p are not Ph; if R₂p = H, R₃p = Me, iso-Pr, iso-Bu, tert-Bu, then both of Ar₁p and R₁p are not tert-methoxyphenyl] are prepared by reaction of RS(O)N:CAR₁pCR₂pR₃pNHP (Ar₁, R₂p, R₃p = same as above; R = bulky group; P = NH₂-protecting group) with organic metal compds. having R₁p group (R₁p = same as above) and deprotection of RS(O)NHCAr₁pR₁pCR₂pR₃pNHP (Ar₁, P, R, R₁p, R₂p, R₃p = same as above). The compds. are prepared from RS(O)N:CR₁pCR₂pR₃pNHP (P, R, R₁p, R₂p, R₃p = same as above) with metal compds. containing Ar₁p group (Ar₁p = same as above). The compds. are intermediates for imidazoline NPY receptor antagonists as antiobesity agents, antidiabetic agents, and polyphagy treatment agents. Tert-Bu N-[(1S)-2-[(R)-(tert-butylsulfinyl)imino]-2-(4-fluorophenyl)-1-methylethyl]carbamate (200 mg) was reacted with 2-fluoro-5-pyridyllithium in PhMe-hexane in the presence of Et₃Al at -78° for 1 h to give 175 mg tert-Bu N-[(1S,2S)-2-[(R)-(tert-butylsulfinyl)amino]-2-(4-fluorophenyl)-2-(6-fluoro-3-pyridyl)-1-methylethyl]carbamate, which was treated with HCl in dioxane at room temperature for 15 min to give (1S,2S)-1-(4-fluorophenyl)-1-(6-fluoro-3-pyridyl)-1,2-propanediamine. 2-(3-Cyanophenyl)-4,4-bis(3-fluorophenyl)-2-imidazoline

showed IC₅₀ of 2.3 nM for inhibiting the binding of [¹²⁵I] peptide YY to human NPY receptor.

IT 357926-26-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyridylethanediamines by addition of sulfinyliminoethylamines

and deprotection as intermediates for imidazoline NPY receptor antagonists)

RN 357926-26-2 CAPLUS

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:636055 CAPLUS

DOCUMENT NUMBER: 135:211050

TITLE: Preparation of imidazoline compounds as antagonists of neuropeptide Y receptor

INVENTOR(S): Sato, Nagaaki; Okamoto, Osamu; Jitsuoka, Makoto; Nagai, Keita; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Fukami, Takehiro

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062738	A1	20010830	WO 2001-JP1312	20010222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2400659	AA	20010830	CA 2001-2400659	20010222
AU 2001034128	A5	20010903	AU 2001-34128	20010222
EP 1264826	A1	20021211	EP 2001-906215	20010222
EP 1264826	B1	20050330		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

AT 292119 E 20050415 AT 2001-906215 20010222





ES 2236178 T3 20050716 ES 2001-1906215 20010222

US 2003158418 A1 20030821 US 2002-204267 20020925

PRIORITY APPLN. INFO.: JP 2000-45042 A 20000222
WO 2001-JP1312 W 20010222

OTHER SOURCE(S): MARPAT 135:211050

GI



AB Compds. represented by the general formula (I) [wherein Ar1, Ar2, Ar3 = aryl or heteroaryl each optionally having substituents selected from cyano, halo, NO₂, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower cycloalkyl-lower alkyl, lower alkenyl, lower alkylamino, di-lower alkylamino, lower alkanoylamino, lower alkylsulfonylamino, arylsulfonylamino, HO, lower alkoxy, halo-lower alkoxy, aryloxy, heteroaryloxy, lower alkylthio, CO₂H, CHO, lower alkanoyl, lower alkoxy carbonyl, CONH₂, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkylsulfonyl, arylsulfonyl, aryl, and heteroaryl; n = 0, 1; R1 = lower cycloalkyl, Ar3, Q, Q1, Q2; R1, R2 = H, lower cycloalkyl, lower alkenyl, lower alkyl optionally having substituents selected from halo, lower alkylamino, di-lower alkylamino, lower alkanoylamino, HO, lower alkoxy, CHO, lower alkoxy carbonyl, lower alkylcarbamoyl, and di-lower alkylcarbamoyl; wherein R10 = R11 = H, or R10 and R11 together represents oxo; X, Y = CH₂, CH₂CH₂, NR₁₂ (wherein R₁₂ = H, lower alkyl), O, S; Z = CH, N; with the proviso that when R2 and R3 are simultaneously hydrogen, Ar1, Ar2 and R1 do not simultaneously represent unsubstituted phenyl] or salts or esters thereof are prepared. These compds. are useful as therapeutic agents for treating various neuropeptide Y (NPY)-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm, and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alc. dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma. Thus, 46.5 mg 2,4-dicyanopyridine and 24 mg ytterbium trifluoromethanesulfonate were added to a solution of 100 mg (2S)-1-(4-fluorophenyl)-1-(6-fluoro-3-pyridyl)-1,2-propanediamine in 0.25 mL PhMe and stirred at 100° for 5 h to give 106 mg optically active (5S)-2-(4-cyano-2-pyridyl)-4-(4-fluorophenyl)-4-(6-fluoro-3-

pyridyl)-5-methyl-2-imidazolidine (II). II in vitro showed IC₅₀ of 1.7 nM for inhibiting the binding of [¹²⁵I]peptide YY to human NPY receptor. Tablet formulations containing 2-(3-cyanophenyl)-4,4-bis(4-fluorophenyl)-2-imidazolidine were prepared


IT 357926-26-2P 357927-31-2P 357927-32-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of imidazoline compds. as antagonists of neuropeptide Y receptor)

RN 357926-26-2 CAPLUS

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 357927-31-2 CAPLUS

CN 2(1H)-Pyridinone, 6-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 357927-32-3 CAPLUS

CN 2(1H)-Pyridinone, 6-[(4R,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall
FILE 'USPATFULL' ENTERED AT 15:28:59 ON 22 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:28:59 ON 22 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 7 SEA FILE=REGISTRY SSS FUL L1
L5 2 SEA L3

=> d 15 1-2 ibib abs hitstr

L5 ANSWER 1 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2005:177944 USPATFULL
TITLE: Novel pyridone derivatives
INVENTOR(S): Sato, Nagaaki, Tsukuba-shi, JAPAN
Nagase, Tsuyoshi, Tsukuba-shi, JAPAN
Nagai, Keita, Tsukuba-shi, JAPAN
Ando, Makoto, Tsukuba-shi, JAPAN
Kanatani, Akio, Tsukuba-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005154025	A1	20050714
APPLICATION INFO.:	US 2003-505476	A1	20030314 (10)
	WO 2003-JP3115		20030314

	NUMBER	DATE
--	--------	------

10/505,476

PRIORITY INFORMATION: JP 2003-2002073120 20020315
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W.,
SUITE 800, WASHINGTON, DC, 20006-1021, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1329


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I): ##STR1## wherein R.¹ is hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, hydroxy, lower alkoxy or aralkyloxy; R.² and R.³ are each independently hydrogen, halogen or halo-lower alkyl; and R.⁴ and R are each independently hydrogen or halogen, is useful as a pharmaceutical composition for the treatment of various diseases related to NPY, for example, cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, etc., nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 604773-87-7P 604773-89-9P 604773-91-3P
(drug candidate; preparation of imidazolinylpyridone derivs. as NPY receptor antagonists)
RN 604773-87-7 USPATFULL
CN 2(1H)-Pyridinone, 6-[(4R,5S)-4-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 604773-89-9 USPATFULL
CN 2(1H)-Pyridinone, 5-fluoro-6-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 604773-91-3 USPATFULL

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4,5-dihydro-5-methyl-4-[6-(trifluoromethyl)-3-pyridinyl]-1H-imidazol-2-yl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 604773-95-7P

(intermediate; preparation of imidazolinylpyridone derivs. as NPY receptor antagonists)

RN 604773-95-7 USPATFULL

CN Pyridine, 6-[(5S)-4-(4-fluorophenyl)-4,5-dihydro-5-methyl-4-[6-(trifluoromethyl)-3-pyridinyl]-1H-imidazol-2-yl]-3-methyl-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2003:226605 USPATFULL

TITLE: Novel imidazonline compounds

10/505,476

INVENTOR(S) :

Sato, Nagaaki, Tsukuba-shi, JAPAN
Okamoto, Osamu, Tsukuba-shi, JAPAN
Jitsuoka, Makoto, Tsukuba-shi, JAPAN
Nagai, Keita, Tsukuba-shi, JAPAN
Kanatani, Akio, Tsukuba-shi, JAPAN
Ishihara, Akane, Tsukuba-shi, JAPAN
Ishii, Yasuyuki, Tsukuba-shi, JAPAN
Fukami, Takehiro, Tsukuba-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158418	A1	20030821
APPLICATION INFO.:	US 2002-204267	A1	20020925 (10)
	WO 2001-JP1312		20010222

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-45042	20000222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3579	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds represented by the general formula (I): ##STR1##

wherein Ar.¹ and Ar.² are each aryl or heteroaryl; R.¹ is lower cycloalkyl, --Ar.³, or a group of the general formula (a), (b) or (c): ##STR2##

and R.² and R.³ are each hydrogen, lower cycloalkyl, lower alkenyl, or optionally substituted lower alkyl (with the proviso that when R.² and R.³ are simultaneously hydrogen, Ar.¹, Ar.² and R.¹ do not simultaneously represent unsubstituted phenyl). The compounds are useful as treating agents for various NPY-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alcohol dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 357926-26-2P 357927-31-2P 357927-32-3P

(preparation of imidazoline compds. as antagonists of neuropeptide Y receptor)

RN 357926-26-2 USPATFULL

CN 2(1H)-Pyridinone, 6-[(5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 357927-31-2 USPATFULL

CN 2(1H)-Pyridinone, 6-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 357927-32-3 USPATFULL

CN 2(1H)-Pyridinone, 6-[(4R,5S)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridinyl)-4,5-dihydro-5-methyl-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>